Aaron Goodman: 2024 ELN AML risk treated with low intensity therapies
Aaron Goodman shared a post on X about a recent paper by Hartmut Döhner et al., commenting:
“2024 European LeukemiaNet (ELN) Acute Myeloid Leukaemia (AML) risk treated with low intensity therapies.
Good!
NPM1 or IDH1 or IDH2 or DDX41 mutated plus.
FLT3 or NRAS or KRAS or TP53 wildtype.
Intermediate:
FLT3 or NRAS or KRAS mutated plus.
TP53 wildtype.
Adverse:
TP53 mutated.”
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations published in Ash Publications.
Additional information
Source: Aaron Goodman/X
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego.
He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.